A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
NCT06066528 on ClinicalTrials.gov · last registry update 2026-08-06
Finished 12 December 2025, after enrolling 755 people. Primary outcome, as filed: Percentage change in body weight from baseline to Week 76. survodutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P3
- Drug
- survodutide
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Enrollment
- 755
- Started
- 2023-11-27
- Primary completion
- 2025-12-12 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage change in body weight from baseline to Week 76
Conditions studied
Obesity · Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the survodutide page for this molecule’s full trial and approval history.